223 related articles for article (PubMed ID: 17070508)
1. IL-2/IL-18 prevent the down-modulation of NKG2D by TGF-beta in NK cells via the c-Jun N-terminal kinase (JNK) pathway.
Song H; Hur DY; Kim KE; Park H; Kim T; Kim CW; Bang S; Cho DH
Cell Immunol; 2006 Jul; 242(1):39-45. PubMed ID: 17070508
[TBL] [Abstract][Full Text] [Related]
2. IDO metabolite produced by EBV-transformed B cells inhibits surface expression of NKG2D in NK cells via the c-Jun N-terminal kinase (JNK) pathway.
Song H; Park H; Kim J; Park G; Kim YS; Kim SM; Kim D; Seo SK; Lee HK; Cho D; Hur D
Immunol Lett; 2011 May; 136(2):187-93. PubMed ID: 21277902
[TBL] [Abstract][Full Text] [Related]
3. RNA interference targeting transforming growth factor-beta enhances NKG2D-mediated antiglioma immune response, inhibits glioma cell migration and invasiveness, and abrogates tumorigenicity in vivo.
Friese MA; Wischhusen J; Wick W; Weiler M; Eisele G; Steinle A; Weller M
Cancer Res; 2004 Oct; 64(20):7596-603. PubMed ID: 15492287
[TBL] [Abstract][Full Text] [Related]
4. Soluble ULBP suppresses natural killer cell activity via down-regulating NKG2D expression.
Song H; Kim J; Cosman D; Choi I
Cell Immunol; 2006 Jan; 239(1):22-30. PubMed ID: 16630603
[TBL] [Abstract][Full Text] [Related]
5. Interleukin-12 improves cytotoxicity of natural killer cells via upregulated expression of NKG2D.
Zhang C; Zhang J; Niu J; Zhou Z; Zhang J; Tian Z
Hum Immunol; 2008 Aug; 69(8):490-500. PubMed ID: 18619507
[TBL] [Abstract][Full Text] [Related]
6. Interleukin-15 improves cytotoxicity of natural killer cells via up-regulating NKG2D and cytotoxic effector molecule expression as well as STAT1 and ERK1/2 phosphorylation.
Zhang C; Zhang J; Niu J; Zhang J; Tian Z
Cytokine; 2008 Apr; 42(1):128-36. PubMed ID: 18280748
[TBL] [Abstract][Full Text] [Related]
7. CD4+CD25+ regulatory T cells inhibit natural killer cell functions in a transforming growth factor-beta-dependent manner.
Ghiringhelli F; Ménard C; Terme M; Flament C; Taieb J; Chaput N; Puig PE; Novault S; Escudier B; Vivier E; Lecesne A; Robert C; Blay JY; Bernard J; Caillat-Zucman S; Freitas A; Tursz T; Wagner-Ballon O; Capron C; Vainchencker W; Martin F; Zitvogel L
J Exp Med; 2005 Oct; 202(8):1075-85. PubMed ID: 16230475
[TBL] [Abstract][Full Text] [Related]
8. Soluble HLA-I-mediated secretion of TGF-beta1 by human NK cells and consequent down-regulation of anti-tumor cytolytic activity.
Ghio M; Contini P; Negrini S; Boero S; Musso A; Poggi A
Eur J Immunol; 2009 Dec; 39(12):3459-68. PubMed ID: 19830740
[TBL] [Abstract][Full Text] [Related]
9. [Immunoediting of natural killer cells by human nasopharyngeal carcinoma cell line: altered expression of KIRs and NKG2D receptors leads to reduction of natural killer cell-mediated cytolysis].
Guo KY; Mei JZ; Yao KT
Nan Fang Yi Ke Da Xue Xue Bao; 2007 Mar; 27(3):247-9. PubMed ID: 17425963
[TBL] [Abstract][Full Text] [Related]
10. Enhancement of natural killer (NK) cell cytotoxicity by fever-range thermal stress is dependent on NKG2D function and is associated with plasma membrane NKG2D clustering and increased expression of MICA on target cells.
Ostberg JR; Dayanc BE; Yuan M; Oflazoglu E; Repasky EA
J Leukoc Biol; 2007 Nov; 82(5):1322-31. PubMed ID: 17711975
[TBL] [Abstract][Full Text] [Related]
11. Platelet-derived transforming growth factor-beta down-regulates NKG2D thereby inhibiting natural killer cell antitumor reactivity.
Kopp HG; Placke T; Salih HR
Cancer Res; 2009 Oct; 69(19):7775-83. PubMed ID: 19738039
[TBL] [Abstract][Full Text] [Related]
12. NKp46 and NKG2D receptor expression in NK cells with CD56dim and CD56bright phenotype: regulation by histamine and reactive oxygen species.
Romero AI; Thorén FB; Brune M; Hellstrand K
Br J Haematol; 2006 Jan; 132(1):91-8. PubMed ID: 16371024
[TBL] [Abstract][Full Text] [Related]
13. TGF-beta and metalloproteinases differentially suppress NKG2D ligand surface expression on malignant glioma cells.
Eisele G; Wischhusen J; Mittelbronn M; Meyermann R; Waldhauer I; Steinle A; Weller M; Friese MA
Brain; 2006 Sep; 129(Pt 9):2416-25. PubMed ID: 16891318
[TBL] [Abstract][Full Text] [Related]
14. A novel immunomodulatory mechanism of ribavirin in suppressing natural killer cell function.
Ogbomo H; Michaelis M; Altenbrandt B; Doerr HW; Cinatl J
Biochem Pharmacol; 2010 Jan; 79(2):188-97. PubMed ID: 19665449
[TBL] [Abstract][Full Text] [Related]
15. Comparative analysis of human NK cell activation induced by NKG2D and natural cytotoxicity receptors.
André P; Castriconi R; Espéli M; Anfossi N; Juarez T; Hue S; Conway H; Romagné F; Dondero A; Nanni M; Caillat-Zucman S; Raulet DH; Bottino C; Vivier E; Moretta A; Paul P
Eur J Immunol; 2004 Apr; 34(4):961-71. PubMed ID: 15048706
[TBL] [Abstract][Full Text] [Related]
16. Induction of NKG2D ligands and subsequent enhancement of NK cell-mediated lysis of cancer cells by arsenic trioxide.
Kim JY; Bae JH; Lee SH; Lee EY; Chung BS; Kim SH; Kang CD
J Immunother; 2008 Jun; 31(5):475-86. PubMed ID: 18463537
[TBL] [Abstract][Full Text] [Related]
17. Resveratrol enhances perforin expression and NK cell cytotoxicity through NKG2D-dependent pathways.
Lu CC; Chen JK
J Cell Physiol; 2010 May; 223(2):343-51. PubMed ID: 20082299
[TBL] [Abstract][Full Text] [Related]
18. Interleukin 2 gene transfer prevents NKG2D suppression and enhances antitumor efficacy in combination with cisplatin for head and neck squamous cell cancer.
Li D; Ronson B; Guo M; Liu S; Bishop JS; Van Echo DA; O'Malley BW
Cancer Res; 2002 Jul; 62(14):4023-8. PubMed ID: 12124336
[TBL] [Abstract][Full Text] [Related]
19. Human tumor-induced and naturally occurring Treg cells differentially affect NK cells activated by either IL-2 or target cells.
Bergmann C; Wild CA; Narwan M; Lotfi R; Lang S; Brandau S
Eur J Immunol; 2011 Dec; 41(12):3564-73. PubMed ID: 21905023
[TBL] [Abstract][Full Text] [Related]
20. Expression of major histocompatibility complex class I chain-related molecule A, NKG2D, and transforming growth factor-beta in the liver of humans with alveolar echinococcosis: new actors in the tolerance to parasites?
Zhang S; Hüe S; Sène D; Penfornis A; Bresson-Hadni S; Kantelip B; Caillat-Zucman S; Vuitton DA
J Infect Dis; 2008 May; 197(9):1341-9. PubMed ID: 18422447
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
